Patient demographic and baseline disease characteristics in the safety run-in population of GRIFFIN
| . | D-RVd (N = 16) . |
|---|---|
| Age, median (range), y | 62.5 (46-65) |
| Category | |
| <65 | 14 (87.5) |
| ≥65 | 2 (12.5) |
| Sex | |
| Male | 8 (50.0) |
| Female | 8 (50.0) |
| Race | |
| White | 11 (68.8) |
| Black or African American | 4 (25.0) |
| Asian | 1 (6.3) |
| ECOG performance status* | |
| 0 | 3 (18.8) |
| 1 | 10 (62.5) |
| 2 | 3 (18.8) |
| ISS disease stage† | |
| I | 12 (75.0) |
| II | 2 (12.5) |
| III | 2 (12.5) |
| Cytogenetic risk profile‡ | |
| Standard | 12 (75.0) |
| High risk | 4 (25.0) |
| Time since diagnosis of multiple myeloma, median (range), mo | 1.6 (0-5) |
| . | D-RVd (N = 16) . |
|---|---|
| Age, median (range), y | 62.5 (46-65) |
| Category | |
| <65 | 14 (87.5) |
| ≥65 | 2 (12.5) |
| Sex | |
| Male | 8 (50.0) |
| Female | 8 (50.0) |
| Race | |
| White | 11 (68.8) |
| Black or African American | 4 (25.0) |
| Asian | 1 (6.3) |
| ECOG performance status* | |
| 0 | 3 (18.8) |
| 1 | 10 (62.5) |
| 2 | 3 (18.8) |
| ISS disease stage† | |
| I | 12 (75.0) |
| II | 2 (12.5) |
| III | 2 (12.5) |
| Cytogenetic risk profile‡ | |
| Standard | 12 (75.0) |
| High risk | 4 (25.0) |
| Time since diagnosis of multiple myeloma, median (range), mo | 1.6 (0-5) |
Data are number of patients (% of total group), unless otherwise specified.
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.
ECOG performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.
The ISS disease stage is based on the combination of serum β2-microglobulin and albumin levels. Higher stages indicate more advanced disease.
Cytogenetic risk was assessed by fluorescence in situ hybridization (local testing); high risk was defined as the presence of del17p, t(4;14), or t(14;16) in patients with available cytogenetic risk data.